Biological Therapies Beyond PARP-Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 MutationsMarta Nerone(Ente Ospedaliero Cantonale), Rossella Graffeo(Ente Ospedaliero Cantonale)Preprints.orgApril 23, 202310.20944/preprints202304.0736.v1Cited by 1SaveCiteExport RISWatch citationsRelated PapersHigh incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel|Annals of Oncology|2001|151Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological Therapies|Cancers|2023|11